There are also reports that compared with using CSII alone, the insulin requirements of T2DM patients in the CSII combined with the troglitazone group decreased by 53%, and those in the CSII combined with the metformin group decreased by 31% [15]. The gene discussed is INS; the disease is type 2 diabetes mellitus.